Skip to main content
Fig. 2 | BMC Oral Health

Fig. 2

From: Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma

Fig. 2

Immune patterns of the cGAS-STING clusters. a, b Five representative immune signatures in the cGAS-STING clusters. c Stroma fraction and leukocyte fraction of the two cGAS-STING clusters. d Immune score and Estimate score of the two cGAS-STING clusters. All P values for significance (< 0.05) represent comparisons via two-tailed t test and multiple t tests with FDR < 0.05. *P value < 0.05, **P value < 0.01, ***P value < 0.001, and ****P value < 0.0001

Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us